Market Cap
$729.1M
WVE
Wave Life Sciences, Inc.
$3.80 ▼ -2.19%
Prev close $3.88Market cap$729.1M
ConsensusStrong Buy
12-mo target$18.06 (+375.8%)
▲ Bullish
Analyst conviction 10/10
Insider Selling Cluster (4 insiders)High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on WVE right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (95%)
Insider Activity
$54.6M buy / $892.6K sell
Insider Net $
$53.7M
Social Sentiment
53° Neutral
SEC Reports
7
Press Releases
2
Price chart 30d -22.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 other
Aug 14, 2026 SEC Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year
Three Wave Life Sciences directors sold a total of ~$132K in open-market shares over a one-week window, with the largest
CLUSTER — Impact 3/10
Aug 12, 2026 Insider
Rawcliffe Adrian sold 12,700 shares
Director @ $5.29 ($67.2K)
Aug 11, 2026 Insider
Wagner Heidi L acquired via exercise 7,000 shares
Director @ $5.97 ($41.8K)
Aug 11, 2026 Insider
May 18, 2026 Press TAKANASHI KEN sold 3,864 shares
Director @ $6.01 ($23.2K)
Wave Life Sciences reported strong updated Phase 1b/2a data for WVE-006 in AATD, showing restoration of wild-type M-AAT
Impact 7/10
Wave Life Sciences reported Q1 2026 EPS of -$0.13, beating consensus estimates of -$0.34 by 61.8%, and revenue of $38.2M
8-K — Impact 7/10
Wave Life Sciences reported Q1 2026 revenue of $38.2M (vs consensus $7.9M) and EPS of -$0.13 (vs consensus -$0.31), repr
PRESS-RELEASE — Impact 7/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
95% rate it Buy or better · 21 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 1, 2026 | Ladenburg Thalmann | INITIATE | Buy | 45% |
| Sep 23, 2026 | JP Morgan | DOWNGRADE | Neutral | 55% |
| Aug 4, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Jul 31, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Jul 31, 2026 | B. Riley Securities | MAINTAIN | Buy | 54% |
| Jul 31, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| May 20, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| May 19, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 4, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Apr 30, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 13 | 1 | 0 | 0 | 95% | |
| Aug 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Jul 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Jun 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% |
Price targets
Where 18 covering analysts think WVE trades over the next 12 months.
$18.06 +375.8% upside Strong Buy
Current$3.80 Low$10.00 Median$14.50 High$42.00 18 analysts
$10.00$42.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment mood +34.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
53°
Neutral
BearishNeutralBullish
Recent posts
WVE: Wall street dosen't know how how to price clinical trial data
▲ 1 · 💬 0· ⚡ 0.5
WVE: Wall street dosen't know how how to price clinical trial data
▲ 1 · 💬 0· ⚡ 0.5
Wave Life Sciences (WVE): Wall Street can't price in Clinical trial data
▲ 1 · 💬 0· ⚡ 0.5
WVE DD
▲ 1 · 💬 0· ⚡ 0.5
My Thesis On $WVE. RA Capital bought $54M after a 50% crash in this Ozempic Competitor.
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
7 SEC filing reports analyzed · 2 bullish, 0 bearish, 1 mixed, 4 neutral · avg impact 5.3/10.Plus 2 press releases.
NEUTRALCLUSTER3/10
Three Wave Life Sciences directors sold a total of ~$132K in open-market shares over a one-week wind
Aug 14, 2026
BULLISH8-K7/10
Wave Life Sciences reported Q1 2026 EPS of -$0.13, beating consensus estimates of -$0.34 by 61.8%, a
Apr 28, 2026
BULLISHPRESS-RELEASE7/10
Wave Life Sciences reported Q1 2026 revenue of $38.2M (vs consensus $7.9M) and EPS of -$0.13 (vs con
Apr 28, 2026
NEUTRALPRESS-RELEASE4/10
Wave Life Sciences (WVE) announced it will report first-quarter 2026 financial results on April 28,
Apr 22, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
other
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approva
Sep 30, 2026
contract
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration pr
Sep 25, 2026
short_volume
Short Volume: WVE — 68.2% short (1.2M / 1.8M)
Short: 1,220,785 | Exempt: 9,515 | TRF Vol: 1,791,174 | Short Ratio: 68.2% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
other
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave’s INHBE GalNAc-siR
Sep 23, 2026
short_volume
Short Volume: WVE — 55.9% short (1.1M / 1.9M)
Short: 1,063,569 | Exempt: 179 | TRF Vol: 1,902,566 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.32 | $-0.36–$-0.25 | -0.1% | -1.0% | 0↑ 1↓ | $0.0B | 15 |
| Next Q | $-0.33 | $-0.42–$-0.24 | -9.6% | +0.6% | 0↑ 1↓ | $0.0B | 14 |
| Current FY | $-1.10 | $-1.22–$-0.87 | 9.0% | +0.7% | 0↑ 3↓ | $0.1B | 15 |
| Next FY | $-1.16 | $-1.68–$-0.07 | -5.1% | +2.8% | 1↑ 2↓ | $0.0B | 16 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.320 | — |
| 7d ago | $-0.320 | -0.001 |
| 30d ago | $-0.317 | -0.003 |
| 60d ago | $-0.323 | +0.003 |
| 90d ago | $-0.307 | -0.014 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 27 transactions. Net $53.7M — $54.6M bought, $892.6K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Rawcliffe Adrian | Director | SELL | 12,700 | $5.29 | $67.2K |
| Aug 11, 2026 | Wagner Heidi L | Director | EXERCISE | 7,000 | $5.97 | $41.8K |
| Aug 11, 2026 | TAKANASHI KEN | Director | SELL | 3,864 | $6.01 | $23.2K |
| Aug 11, 2026 | Wagner Heidi L | Director | SELL | 7,000 | $6.01 | $42.1K |
| Aug 11, 2026 | Tan Aik Na | Director | SELL | 432 | $6.01 | $2.6K |
| Mar 30, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 971,091 | $6.50 | $6.3M |
| Mar 27, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 2,495,623 | $6.43 | $16.0M |
| Mar 26, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 4,954,558 | $6.06 | $30.0M |
| Mar 26, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 351,224 | $6.38 | $2.2M |
| Mar 23, 2026 | TAKANASHI KEN | Director | CONVERT | 3,901,348 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for WVE.
Shares short
17,637,783
Settlement Sep 15, 2026
Change vs prior
+8.3%
Semi-monthly cycle
Days to cover
5.2
At avg daily volume
Of shares outstanding
≈8.9%
Estimate — not % of float
All WVE filing & press-release reports (9)
- CLUSTER reportAug 14, 2026
- PRESS-RELEASE reportMay 18, 2026
- 8-K reportApr 28, 2026
- PRESS-RELEASE reportApr 28, 2026
- PRESS-RELEASE reportApr 22, 2026
- DEFA14A reportApr 15, 2026
- 8-K reportApr 15, 2026
- PRESS-RELEASE reportMar 26, 2026
- 8-K reportFeb 26, 2026